A CHEST review examines low-dose CT screening in people without a substantial smoking history, using China's large programmes as the case study. Benefit from screening is established by trials in heavily tobacco-exposed populations. In China, a large share of lung cancers occur in people who have never smoked or smoked little.
The authors argue that finding more early-stage cancers is not enough to show benefit, because of lead-time and length bias and overdiagnosis; a fall in advanced-stage disease is the better signal. Risk models built in smokers perform worst in exactly the people expanded programmes would target. They cite data from China and South Korea suggesting that spreading CT screening into average-risk populations may add more overdiagnosis than benefit.
This is an argued review, not new data, and it does not address India directly. Its framework applies wherever screening is offered to people outside the trial-proven smoking-risk groups.
- Low-dose CT screening has proven mortality benefit in people with substantial smoking history.
- Be cautious about offering screening to never-smokers outside a structured programme or study.
- Discuss overdiagnosis and false positives when patients ask for CT screening without clear risk.
- Ask about other exposures, such as biomass smoke and occupational dusts, when assessing lung cancer risk.
Why it matters
Screening that finds more cancers can still do more harm than good.
Don't overread it
This is a narrative argument, not a trial; it does not show that screening non-smokers is harmful either.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free